Please login to the form below

Not currently logged in
Email:
Password:

AZ's Brilinta approved in Canada

Health Canada has approved AstraZeneca's Brilinta to prevent blood clots in patients with acute coronary syndrome

Health Canada has approved AstraZeneca's (AZ) Brilinta (ticagrelor) for the secondary prevention of atherothrombotic events, such as blood clots, in patients with acute coronary syndrome.

The approval comes seven months after the drug was denied approval by the US Food and Drug Administration (FDA), with studies demonstrating that patients were more likely to experience heart problems with Brilinta than rival drug Plavix (clopidogrel), despite AZ's treatment having greater efficacy.

The FDA did not request additional studies, but did ask for additional analyses of the data from the company's PLATO trial. The drug remains in review in the US, as well as Russia, India and China.

Including Canada, Brilinta has now been approved in 33 countries, including in the European Union under the name Brilique.

1st June 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
PRMA Consulting Ltd

PRMA Consulting is an independent consultancy solving some of the most challenging pricing, reimbursement and market access issues facing international...

Latest intelligence

From lay summaries to patient engagement programmes: how patient-centricity is finally becoming a reality
How pharma is progressing their commitment in patient engagement...
Cuttsy+Cuttsy awarded CPD Platinum by the IPA
Four years after being awarded Gold for their continuous professional development (CPD) Cuttsy+Cuttsy (C+C) have reached another milestone and been awarded Platinum accreditation....
Breaking Bad
Six behaviours separate the good brand teams from the bad...

Infographics